Tag Archives: marketing application

Combination Products: What’s New?

A monoclonal antibody combined with a therapeutic drug. An EpiPen®. A drug packaged with its delivery device. All of these are examples of combination products. A combination product, according to the FDA, is “a product composed of any combination of … Continue reading

Posted in Clinical Trials, FDA, Industry News | Tagged , , , , , , , , , , , , , , , , , , , , , , , | 1 Comment

FDASIA, Part 1: The “UFAs”

On 09 July 2012, the Food and Drug Administration Safety and Innovation Act (FDASIA, otherwise known as PDUFA V) was signed into law.  In a 4-part series, we will cover the major changes in FDASIA as follows: Part 1: The … Continue reading

Posted in FDA, Industry News, Regulatory Strategy | Tagged , , , , , , , , , , , , , , , , , , , , | 4 Comments

Stem Cells: Which Way to the Clinic? (Updated!)

For over two decades, the potential of stem cell therapy to cure some of our most devastating diseases has been touted by the media.  A Google search of “stem cell research” yields over 57 million results, and yet, in mid-2012, … Continue reading

Posted in FDA, Industry News | Tagged , , , , , , , , , , | 3 Comments

New FDA Guidances from April 2012

Here’s a list of the notable guidances released by FDA in April 2012. Continue reading

Posted in FDA, Regulatory Strategy | Tagged , , , , , , | Comments Off on New FDA Guidances from April 2012

FDA Reorganizes Oncology and Hematology Divisions

When we are no longer able to change a situation, we are challenged to change ourselves. Victor Frankl The FDA recently announced that it is reorganizing three divisions (Hematology Products, Drug Oncology Products, and Biologic Oncology Products) from the Office … Continue reading

Posted in Clinical Trials, FDA, Industry News, Regulatory Strategy | Tagged , , , , , , | Comments Off on FDA Reorganizes Oncology and Hematology Divisions